Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance
News Sep 05, 2014
Rosetta Genomics Ltd. has announced that the company has entered into a strategic alliance with Moffitt Cancer Center to discover, develop and commercialize a variety of microRNA-based cancer diagnostics.
The three-year alliance brings together the resources and talents of Moffitt, a National Cancer Institute-designated Comprehensive Cancer Center, with those of Rosetta Genomics, an industry-leading developer of microRNA-based diagnostics, to stimulate new projects and collaborations for the development of diagnostics in areas of unmet medical need. Rosetta will provide funding for Moffitt investigator-initiated projects that align with Rosetta's strategic priorities.
Rosetta has a proprietary discovery microarray platform with over 2,500 human microRNAs, along with a proprietary RT-PCR platform. Additionally, Rosetta has bioinformatics and microRNA wet lab expertise, with approximately 50 peer-reviewed publications across multiple cancers and other disease states and on many tissue types and body fluids. This strategic alliance will leverage Rosetta's capabilities and expertise.
Moffitt has internationally-renowned researchers including medical oncologists and pathologists who have first-hand knowledge of unmet medical needs in cancer patient management. The research enterprise at Moffitt is composed of multidisciplinary research programs with more than 160 faculty members focused on basic, population, clinical, and translational research.
"We are excited about the opportunity to develop novel cancer diagnostics for important, unmet medical needs based on our proprietary microRNA platform technologies with Moffitt's world-class team of oncologists and pathologists who have dedicated their careers to advancing cancer patient care," noted Kenneth A. Berlin, president and chief executive officer of Rosetta Genomics. "New molecularly targeted therapies continue to drive the need for more accurate classification of tumor types, which helps to guide treatment decisions, monitor therapy, predict outcomes and more. Responding to these unmet medical needs, the overall purpose of this alliance is to advance the care of cancer patients through the development of diagnostic assays based on Rosetta's microRNA technology, which with its high reproducibility, robustness and accuracy is well suited to provide this valuable clinical information."
"Moffitt is committed to bringing innovative oncology diagnostics to patients in order to optimize clinical outcomes. This goal is particularly well aligned with Rosetta's expertise, and we are pleased to partner with a known leader in microRNA technology," said Anthony Magliocco, M.D., chair of the Anatomical Pathology Program and executive director of the Morsani Molecular Diagnostics Laboratory at Moffitt.
Magliocco continued, "We look forward to working with the Rosetta team on research collaborations for the development of new, effective diagnostic assays and novel tests. This alliance should produce cutting-edge research and data that can be the subject of scientific publications and presentations. Importantly, the development of such tests will benefit patients, who are the ultimate focus of our work at Moffitt."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.